Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 7679 results

  1. Cytokine adsorption technologies for treating respiratory failure in people with COVID-19

      Status ...

    Medical technologies guidance
    Topic selection

  2. Archimedes for biopsy of suspected lung cancer

      Status ...

    Medical technologies guidance
    Topic selection

  3. Upadacitinib for treating giant cell arteritis [ID6299]

    Awaiting development [GID-TA11330] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Actim Pancreatitis for diagnosing acute pancreatitis

      Status ...

    Diagnostics guidance
    Topic selection

  5. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

      Status ...

    Medical technologies guidance
    Topic selection

  6. PCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms

      Status ...

    Medical technologies guidance
    Topic selection

  7. Spartan RX point-of-care CYP2C19 test

      Status ...

    Diagnostics guidance
    Topic selection

  8. Healthy.io test for home testing of urine albumin to creatinine ratio

      Status ...

    Diagnostics guidance
    Topic selection

  9. FebriDx for C-reactive protein and myxovirus resistance protein A testing

      Status ...

    Diagnostics guidance
    Topic selection

  10. Helge for detecting haemolysis

      Status ...

    Diagnostics guidance
    Topic selection

  11. MolecuLight i:X for wound imaging

    The panel agreed the technology is not appropriate to be selected for guidance development as there is insufficient evidence.   ...

    Medical technologies guidance
    Topic selection

  12. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

      Status ...

    Medical technologies guidance
    Topic selection

  13. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development